We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exagen Inc. (XGN) Stock Jumps 6.8%: Will It Continue to Soar?
Read MoreHide Full Article
Exagen Inc. (XGN - Free Report) shares rallied 6.8% in the last trading session to close at $20.88. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 16.5% gain over the past four weeks.
This marks the third consecutive trading day of Exagen’s price increase driven by the optimism around its AVISE suite of testing solutions, which exhibited an earlier-than-expected recovery. The rebound came courtesy of the serious nature of autoimmune disorders, and the sophistication offered to patients and healthcare providers through the AVISE test offerings. In fact, despite the pandemic scenario, the estimates are showing sales recovery for the fourth quarter 2020 (slated to release on Mar 16) with the Zacks Consensus Estimate of $10.4 billion indicating growth of 1.8% year over year. Market is also upbeat about the company commencing 2021 with a partnership with Boston’s Tufts Medical Center to offer AVISE testing in an effort to aid patients suffering from autoimmune diseases with a more accurate testing option, while expanding access to testing at the same time.
Price and Consensus
This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of -55.6%. Revenues are expected to be $10.39 million, up 1.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Exagen Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on XGN going forward to see if this recent jump can turn into more strength down the road.
Image: Bigstock
Exagen Inc. (XGN) Stock Jumps 6.8%: Will It Continue to Soar?
Exagen Inc. (XGN - Free Report) shares rallied 6.8% in the last trading session to close at $20.88. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 16.5% gain over the past four weeks.
This marks the third consecutive trading day of Exagen’s price increase driven by the optimism around its AVISE suite of testing solutions, which exhibited an earlier-than-expected recovery. The rebound came courtesy of the serious nature of autoimmune disorders, and the sophistication offered to patients and healthcare providers through the AVISE test offerings. In fact, despite the pandemic scenario, the estimates are showing sales recovery for the fourth quarter 2020 (slated to release on Mar 16) with the Zacks Consensus Estimate of $10.4 billion indicating growth of 1.8% year over year. Market is also upbeat about the company commencing 2021 with a partnership with Boston’s Tufts Medical Center to offer AVISE testing in an effort to aid patients suffering from autoimmune diseases with a more accurate testing option, while expanding access to testing at the same time.
Price and Consensus
This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of -55.6%. Revenues are expected to be $10.39 million, up 1.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Exagen Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on XGN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>